A recent clinical trial at the MD Anderson Cancer Center has challenged the established local consolidative therapy paradigm for patients with non-small cell lung cancer (NSCLC). Published this week, the … Read More
Immunotherapy is showing emerging potential for treating rising rates of gynecological tumors, according to recent medical analyses. Clinical approaches leveraging checkpoint inhibitors and cellular mechanisms are being evaluated across global … Read More
An accurate bladder cancer diagnosis is vital because it directly dictates precise staging, determines the efficacy of targeted therapies like immunotherapy, and prevents the overtreatment of indolent disease or undertreatment … Read More
In a phase 1 dose-escalation trial published in Nature Medicine on August 6, 2026, researchers found that intracranial delivery of B7-H3-targeting chimeric antigen receptor (CAR) T cells in patients with … Read More
Researchers have issued an Author Correction for a Phase 1 trial published in Nature Medicine, clarifying methodological details regarding multi-antigen-targeting T cells for pediatric central nervous system (CNS) tumors. This … Read More
Patients with pretreated metastatic renal cell carcinoma demonstrated improved clinical outcomes when receiving a combination of pembrolizumab and denosumab. Recent clinical findings suggest this dual-agent approach may offer a viable … Read More
As Merck’s Keytruda (pembrolizumab) approaches its patent cliff, the oncology sector is pivoting toward a new standard of care: the strategic pairing of Antibody-Drug Conjugates (ADCs) with next-generation immunotherapies. This … Read More
_on_a_T-cell_is_binding_to_a_molecule_on_a_cancer_-_Alpha_Tauri_3D_Graphics_M1_dc8762afeaee4937ad644739f274c7a5-620x480.jpg)
Experimental CAR T-cell therapy has demonstrated efficacy in treating solid tumors, according to clinical data reported by News-Medical this week. The first-in-class treatment modifies a patient’s own T-cells to recognize … Read More
Researchers have identified a specific probiotic metabolite that significantly suppresses melanoma tumor growth in preclinical mouse models. By modulating the gut microbiome, this microbial byproduct enhances the body’s anti-tumor immune … Read More
A study published this week in Science Translational Medicine reports that engineered CAR T cells effectively target bladder cancer in murine models, marking a potential breakthrough in immunotherapy. The research, … Read More
